Coronary Revascularization in Patients with Obstructive Sleep Apnea Syndrome
DOI:
https://doi.org/10.1532/HSF98.20061072Abstract
Background. There is a paucity of clinical information regarding therapy for ischemic heart disease (IHD) in patients with obstructive sleep apnea syndrome (OSAS). We evaluated our experience with surgical revascularization in this subset of patients.
Methods. Between January 1998 and April 2001, 20 patients with OSAS underwent isolated coronary artery bypass grafting (CABG). Outcomes were compared to a matched control group consisting of 65 patients.
Results. Patients with OSAS and the controls were similar with regard to age (65.8 years versus 65.2 years), ejection fraction (44.5% versus 46.9%), and systolic blood pressure (141 mmHg versus 142 mmHg). However, they were comparatively heavier (212 lb versus 188 lbs, P < .03), had higher pulmonary artery pressures (42 mmHg versus 34 mmHg, P < .001), higher pulmonary capillary wedge pressures (17 mmHg versus 14 mmHg, P < .01), higher left ventricular end diastolic pressures (20 mmHg versus 18 mmHg, P < .04), and a greater incidence of diabetes (55% versus 30%, P = .049). Patients with OSAS were more likely to require prolonged ventilation (40% versus 0%, P < .001) and tracheostomy (10% versus 0%, P = .01) and have a protracted intensive care unit (ICU) course (9 days versus 3 days, P = .002) and hospitalization (24 versus 13, P = .003). There were no peri-operative deaths, and both groups had significant improvement in angina and functional class. At a mean follow-up of 59 months, angina recurrence was 10% and survival was 95% in patients with OSAS.
Conclusion. Patients with OSAS and IHD requiring coronary revascularization have substantial risk for pulmonary morbidity that impacts the duration of hospitalization but not mortality. Good symptom control and early to mid-term survival may be achieved in this subset of patients with aggressive peri-operative management of their OSAS.
References
Bady E, Achkar A, Pascal S, Orvoen-Frija E, Laaban JP. 2000. Pulmonary arterial hypertension in patients with sleep apnoae syndrome. Thorax 55:934-9.nBradley TD, Rutherford R, Grossman RF, et al. 1985. Role of daytime hypoxemia in the pathogenesis of right heart failure in the obstructive sleep apnea syndrome. Am Rev Respir Dis 131:835-9.nDyken ME, Somers VK, Yamada T, Ren ZY, Zimmerman MB. 1996. Investigating the relationship between stroke and obstructive sleep apnea. Stroke 27:401-7.nHung J, Whitford EG, Parsons RW, Hillman DR. 1990. Association of sleep apnoea with myocardial infarction in men. Lancet 336:261-4.nKaneko Y, Floras JS, Usui K, et al. 2003. Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea. N Engl J Med 348:1233-41.nKopelman PG. 1992. Altered respiratory function in obesity: sleep disordered breathing and the Pickwickian syndrome. In: Björntorp P, Brodoff BN, eds. Obesity. Philadelphia, Pa: Lippincot; 568-75.nLeung RS, Bradley TD. 2001. Sleep apnea and cardiovascular disease. Am J Respir Crit Care Med 164:2147-65.nLittner M, Alessi C. 2002. Obstructive sleep apnea: asleep in our consciousness no more. Chest 121:1729-30.nMooe T, Rabben T, Wiklund U, Franklin KA, Eriksson P. 1996. Sleepdisordered breathing in men with coronary artery disease. Chest 109:659-63.nMooe T, Rabben T, Wiklund U, Franklin KA, Eriksson P. 1996. Sleep-disordered breathing in women: occurrence and association with coronary artery disease. Am J Med 101:251-6.nNarkiewicz K, Montano N, Cogliati C, van de Borne PJ, Dyken ME, Somers VK. 1998. Altered cardiovascular variability in obstructive sleep apnea. Circulation 98:1071-7.nPeker Y, Hedner J, Kraiczi H, Loth S. 2000. Respiratory disturbance index: an independent predictor of mortality in coronary artery disease. Am J Respir Crit Care Med 162:81-6.nPeled N, Abinader EG, Pillar G, Sharif D, Lavie P. 1999. Nocturnal ischemic events in patients with obstructive sleep apnea syndrome and ischemic heart disease: effects of continuous positive air pressure treatment. J Am Coll Cardiol 34:1744-9.nPeppard PE, Young T, Palta M, Skatrud J. 2000. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 342:1378-84.nPhillips BG, Narkiewicz K, Pesek CA, Haynes WG, Dyken ME, Somers VK. 1999. Effects of obstructive sleep apnea on endothelin-1 and blood pressure. J Hypertens 17:61-6.nSanner BM, Doberauer C, Konermann M, Sturm A, Zidek W. 1997. Pulmonary hypertension in patients with obstructive sleep apnea syndrome. Arch Intern Med 157:2483-7.nShahar E, Whitney CW, Redline S, et. al. 2001. Sleep disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med 163:19-25.nShamsuzzaman AS, Gersh BJ, Somers VK. 2003. Obstructive sleep apnea: implications for cardiac and vascular disease. JAMA 290:1906-14.nVenugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. 2002. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 106:1439-1.nWeitzenblum E, Krieger J, Apprill M, et al. 1988. Daytime pulmonary hypertension in patients with obstructive sleep apnea syndrome. Am Rev Respir Dis 138:345-9.nWolk R, Kara T, Somers VK. 2003. Sleep-disordered breathing and cardiovascular disease. Circulation 108:9-12.nWoolard KJ, Phillips DC, Griffiths HR. 2002. Direct modulatory effect of C-reactive protein on primary human monocyte adhesion to human endothelial cells. Clin Exp Immunol 130:256-62.nYoung T, Peppard PE, Gottlieb DJ. 2002. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med 165:1217-39.n
